Fluvoxamine is an SSRI that may improve outcomes in COVID-19 when administered in the outpatient setting. This small trial published in JAMA two days ago looks into the positive effects of this therapy to prevent clinical worsening of patients with COVID.
Show Notes: https://eddyjoemd.com/fluvoxamine
Receive a FREE audiobook (TWO for Amazon Prime members) with your FREE 30-day trial by using my link for Audible: CLICK HERE! You will be reminded when your trial is ending, by the way. 😉
Although great care has been taken to ensure that the information in this podcast are accurate, eddyjoe, LLC shall not be held responsible or in any way liable for the continued accuracy of the information, or for any errors, omissions or inaccuracies, or for any consequences arising therefrom.
My website: www.eddyjoemd.com
Instagram: www.instagram.com/eddyjoemd
Twitter: www.twitter.com/eddyjoemd
Facebook: www.facebook.com/eddyjoemd
Podcast: https://anchor.fm/eddyjoemd
My Amazon store for resources you may find helpful: www.amazon.com/shop/eddyjoemd
Citation: Lenze EJ, Mattar C, Zorumski CF, Stevens A, Schweiger J, Nicol GE, Miller JP, Yang L, Yingling M, Avidan MS, Reiersen AM. Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial. JAMA. 2020 Nov 12. doi: 10.1001/jama.2020.22760. Epub ahead of print. PMID: 33180097.
